This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CryoLife Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Leading medical device and tissue processing company, CryoLife, Inc. (CRY) rallied to a new 52-week high of $20.20 on Jun 27, eventually closing a little lower at $19.65.
Ensign Group (ENSG) Acquires Facilities in Texas & Wisconsin
by Zacks Equity Research
The Ensign Group, Inc. (ENSG) recently announced that it acquired the real estate and operations of two assisted living facilities in Texas and three assisted living facilities in Wisconsin.
Express Scripts Gains from Increased Generic Utilization
by Zacks Equity Research
On Jun 27, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).
Varian Rides on Oncology and Proton Therapy Businesses
by Zacks Equity Research
On Jun 27, we issued an updated research report on Palo Alto, CA-based Varian Medical Systems Inc. (VAR).
What Drove Becton, Dickinson (BDX) to a New 52-Week High?
by Zacks Equity Research
Share price of Becton, Dickinson and Company (BDX) , based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $196.01 on Jun 27.
Quintiles' (Q) OCE Software to Simplify Commercial Functions
by Zacks Equity Research
QuintilesIMS (Q) announced the general availability of Orchestrated Customer Engagement (OCE) software to streamline pharmaceutical commercial functions.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes
by Zacks Equity Research
Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.
Penumbra (PEN) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company.
ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System
by Zacks Equity Research
Medical technology company, ConforMIS, Inc. (CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.
Merit Medical Embosphere Gets FDA de novo Classification
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) recently announced the receipt of 513(f)(2) (de novo) classification for Embosphere Microspheres from the FDA to expand its indication in the prostatic artery embolization (PAE) space.
Quest Diagnostics Enhances Blueprint for Athletes Service
by Zacks Equity Research
Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.
Why Investors Should Buy Align Technology (ALGN) Right Now
by Zacks Equity Research
Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
by Zacks Equity Research
The Cooper Companies (COO) rallied to a new 52-week high of $247.80 on Jun 22, closing a tad lower at $245.06.
Evolent Health (EVH) Prices 4.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 4.5 million shares of Class A common stock at $25.90 per share.
Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.
Here's Why Henry Schein is Worth Adding to Your Portfolio
by Zacks Equity Research
Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.
PRA Health Hits a 52-Week High on Strategic Acquisitions
by Zacks Equity Research
Leading global contract research organization PRA Health Sciences (PRAH) rallied to a new 52-week high of $78.30 on Jun 21, closing a little lower at $77.21.
Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.
Luminex (LMNX) Banks on Portfolio Strength, View Impressive
by Zacks Equity Research
On Jun 21, we issued an updated research report on Austin, TX-based Luminex Corp (LMNX) -- a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry.
Why Investors Should Buy Edwards Lifesciences (EW) Right Now
by Zacks Equity Research
Leading CA-based medical equipment major Edwards Lifesciences Corporation (EW) is currently on a healthy growth trajectory.
Why Quest Diagnostics (DGX) is a Suitable Pick for Investors
by Zacks Equity Research
Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.
Lantheus (LNTH) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Lantheus Holdings, Inc. (LNTH) has rallied 28.2% over the last three months, ahead of the S&P 500's 4.3% gain.
Baxter (BAX) Scales 52-Week High: What's Behind the Rally
by Zacks Equity Research
Baxter International Inc. (BAX) scaled a new 52-week high of $60.47 on Jun 21, closing a bit lower at $60.05.